Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02340156|
Recruitment Status : Terminated
First Posted : January 16, 2015
Results First Posted : March 3, 2021
Last Update Posted : March 3, 2021
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|RECURRENT GLIOBLASTOMA||Genetic: SGT-53 Drug: Temozolomide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Combined Temozolomide and Targeted P53 Gene Therapy (SGT-53) for Treatment of Patients With Recurrent Glioblastoma|
|Study Start Date :||December 2014|
|Actual Primary Completion Date :||November 2018|
|Actual Study Completion Date :||November 2018|
Experimental: SGT-53 with Temozolomide
SGT-53, at 3.6 mg DNA/infusion, will be administered twice weekly in a 28 day cycle starting on Day 1 (cycle 1), Day 29 (cycle 2) and Day 57 (cycle 3). Temozolomide (TMZ) will be administered by mouth daily on days 9-13 of each cycle. Patients who are responding to treatment may receive three additional cycles of SGT-53/TMZ therapy or continue on TMZ alone at investigator's discretion. Surgical resection of recurrent or progressive tumor for tumor analysis is an optional procedure. In these individuals SGT-53, at 3.6 mg DNA/infusion, will be administered twice (on days -1 and -3) in the week prior to surgery. Surgical resection is Day 0. 14-21 days post operatively and having recovered from the effects of surgery, the patients will then start cyclical TMZ with SGT-53 as described above.
SGT-53, at 3.6 mg DNA per infusion, will be administered twice per week for 3 weeks (on Day 1, 4, 8, 11, 15 and 18 of each cycle) for 3 cycles. If SGT-53-related toxicity occurs, the dose of SGT-53 will be de-escalated to 2.4 or 1.2 mg DNA/infusion when appropriate.
TMZ will be administered orally on days 9-13 of each cycle. In cycle 1, the dose of TMZ will be 150 mg/m². If the TMZ-related toxicities are tolerated in cycle 1, the dose of TMZ will be escalated to 200 mg/m² for cycle 2 and beyond. If TMZ-related toxicity occurs, the dose if TMZ will be de-escalated to 125 mg/m² (dose level -1), 100 mg/m² (dose level -2) or 75 mg/m² (dose level -3) when appropriate.
Other Name: Temodar
- Tumor Response [ Time Frame: 6 months ]The 6 month progression-free survival (PFS) was evaluated using RANO Response Criteria.
- Incidence of Treatment-Emergent Adverse Events [ Time Frame: Study drug initiation through 30 days after the last dose of study drug or EOS, whichever is later, approximately 90 days. ]The safety of the combination of SGT-53 and Temozolomide was assessed by analysis of adverse experiences, clinical laboratory tests and physical examinations.
- Progression-free Survival (PFS) [ Time Frame: From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months. ]Progression-free survival is defined as the time from the date of enrollment to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurs earlier. Subjects who do not have disease progression or have not died will be censored at the date of the last tumor assessment on or prior to the clinical cutoff.
- Overall Survival (OS) [ Time Frame: From date of registration until the date of death from any cause, assessed up to 180 months. ]Overall survival is defined as the time from the date of enrollment to the date of death from all causes.
- Anti-tumor Activity [ Time Frame: From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months. ]The anti-tumor activity of the combination of SGT-53 and Temozolomide was determined based upon the RANO criteria.
- Induction of Apoptosis [ Time Frame: 3 days ]Flow cytometry or histological examination was used to determine the level of apoptosis induced by SGT-53 in tumors resected 3 days after the first SGT-53 infusion (optional procedure)
- Nanoparticle Tumor Delivery [ Time Frame: 3 days ]As an indicator of nanoparticle delivery to the tumors, DNA PCR was used to determine the presence of SGT-53 delivered exogenous wt p53 in the tumors. This analysis will be performed on any tumors resected 3 days after the first SGT-53 infusion (optional procedure)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Histologically confirmed glioblastoma or gliosarcoma in 1st, 2nd or 3rd relapse.
- Radiographic demonstration of disease progression following prior therapy
- Measurable disease on MRI performed within 14 days prior to registration.
- Male or female patients ≥ 18 years of age.
Recurrent disease with an:
- interval of ≥ 3 months following radiotherapy + TMZ;
- interval of ≥ 14 days between end of surgery and start of protocol therapy for patients who have undergone surgery for recurrent disease.
- Patients who tolerated previous administration with TMZ
Recovery from the effects of prior therapy:
- 4 weeks from cytotoxic agents
- 6 weeks from nitrosoureas
- 4 weeks from any investigational agent
- 1 week from non-cytotoxic agents
- 12 weeks from radiotherapy
- Karnofsky performance status ≥ 60%.
- Complete blood count/differential at screening with adequate bone marrow function
- If patient is receiving steroids, must be on stable or decreasing steroid dose within 5 days prior to treatment initiation with SGT-53.
- Patients must be willing to forego other cytotoxic and non-cytotoxic drug or radiation therapy against the tumor while enrolled in the study.
- Women of childbearing potential must have a negative serum beta-HCG pregnancy test documented within 3 days prior to study initiation.
- Women of childbearing potential must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatment
- Males not naturally or surgically sterile, who have a female partner of childbearing potential, must agree to use two reliable methods of contraception from screening and up to 30 days after discontinuation of study treatment
- Acceptable liver function
- Acceptable blood sugar control
- Urinalysis: No clinically significant abnormalities.
- PT and PTT ≤ 1.5 X ULN
- Have recovered from any previous therapy side effects or toxicities
- Organ function characterized by ≤ Grade 1
- Histology other than astrocytoma grade IV
- Tumor foci detected below the tentorium or beyond the cranial vault.
- Glioblastoma or gliosarcoma disease with leptomeningeal spread.
- Patients with a history of any other cancer, unless in complete remission, and off all therapy for that disease for a minimum of 5 years
- Patients with serum aspartate aminotransferase, alanine aminotransferase > 2.5 X the upper limit of normal (ULN) and bilirubin >1.5 ULN
- Moderate to severe hepatic impairment.
- Positive results from HIV serology testing, if any available.
- Supine systolic blood pressure < 100 mmHg or supine diastolic blood pressure < 50 mmHg at screening and baseline
- Renal insufficiency or serum creatinine >1.5 X ULN at screening.
- Females who are pregnant or lactating or plan to become pregnant during the course of this study.
- Substance or alcohol abuse or dependence, within 12 months prior to screening.
- Prior chemotherapy for recurrent GBM with nitrosourea compounds including Gliadel® wafers or bevacizumab.
- Prior focal radiotherapy within 3 months of screening.
- Planned treatment, or treatment with any investigational drug within 4 weeks prior to screening.
- Severe, active co-morbidity
- Patients who are currently taking Coumadin or Coumadin derivatives other than to maintain patency of venous access lines.
- Requiring renal dialysis
- Receiving hematopoietic growth factors
- Have significant baseline neuropathies
- Had prior exposure to gene vector delivery products within 6 months
- Any condition that prevents compliance with the protocol or adherence to therapy.
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
- Treated with antibiotics for infection within one week prior to study entry.
- Fever (> 38.1°C)
- Have diastolic blood pressure of > 90 mm Hg resting at baseline despite medication.
- Serious nonmalignant disease
- Enrollment in a concomitant clinical study
- Have a history of hypersensitivity reaction to any of the components of Temozolomide
- Have a history of hypersensitivity to dacarbazine (DTIC)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02340156
|United States, Texas|
|MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|China Medical University Hospital|
|Taichung, Taiwan, 40447|
|Principal Investigator:||John deGroot, MD||M.D. Anderson Cancer Center|
Documents provided by SynerGene Therapeutics, Inc.:
|Responsible Party:||SynerGene Therapeutics, Inc.|
|Other Study ID Numbers:||
|First Posted:||January 16, 2015 Key Record Dates|
|Results First Posted:||March 3, 2021|
|Last Update Posted:||March 3, 2021|
|Last Verified:||February 2021|
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action